Minocycline Treatment in Retinitis Pigmentosa

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d), administered for 6 months, for the treatment of patients with retinitis pigments(RP).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• Clinical diagnosis of Retinitis Pigmentosa: nyctalopia, visual field constriction and loss of central vision; degeneration of peripheral rod photoreceptor and retinal pigment epithelium cells.

• Age from 18 to 60 years old.

• BCVA >20/100(0.2).

• Full-field cone electroretinogram amplitude to 30-Hz flashes >0uV.

• Written informed consent is provided.

Exclusion Criteria:

• Glucocortticoids or tetracycline were used within 3 months.

• Vitamin A, DHA and other neurotrophic drugs were used within 3 months.

• Other ocular diseases or fundus diseases except cataract: glaucoma, diabetic retinopathy, retinal detachment.

• Tetracycline or minocycline allergy or intolerance.

• Renal or hepatic insufficiency.

• History of thyroid neoplasm.

• History of idiopathic intracranial hypertension.

• Pregnant or lactating females.